Corvia MedicalAnnounced the completion of a new round of $55 million financing, invested by Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and two strategic investment institutions. This round of financing will be used to advance the ongoing RESPONDER-HF trial.Remarks:RESPONDER-HF Trial isA double-blind, randomized, sham-controlled confirmatory study on the Corvia atrial shunt device. The trial has currently been launched in more than 65 medical institutions across three continents and is expected to generate pivotal clinical data to support the approval of the device by the U.S. Food and Drug Administration (FDA).Corvia Atrial ShuntIs expected to become a breakthrough therapy for the treatment of heart failure with preserved ejection fraction and mildly reduced ejection fraction (HFpEF/HFmrEF).
Executive Evaluation
"At this critical stage of our FDA submission for the Corvia Atrial Shunt, we are deeply grateful for the steadfast support of our long-term partners. Their continued commitment will accelerate our mission to bring a revolutionary therapy to millions of heart failure patients worldwide."
---George Fazio Corvia MedicalChief Executive Officer
"We firmly believe that Corvia has the potential to revolutionize the treatment landscape for heart failure, a vision shared by our investors. With this financing, we are fully committed to advancing the product approval process, bringing this breakthrough therapy to patients as soon as possible."
---Paul LaViolette Corvia MedicalChairman of the Board
2022Corvia MedicalPublicationCorviaClinical Data for Atrial Shunt Devices in Heart Failure Treatment Shows Poor Results (After Corvia TreatmentDid not reduce the incidence of heart failure or improve health outcomes, results withProsthesisNo Difference in Surgical Group). This caused the entire atrial shunt device to enter a low point. However, with subsequent developments...Corvia Medical、Mainstream players like V-Wave subsequently proved effective in treating some heart failure patients with clinical data, and the market began to warm up again.Wait until goingJohnson & Johnson inAcquisition for $600 MillionV-Wave, bringing atrial shunt devices back to the forefront of the cardiovascular field, has restored investors' confidence in these devices. Subsequently, many foreign atrial shunt innovators have secured new funding (for example,Adona Medical Completes$33.5 million in financing,Alleviant MedicalCompleted a $90 million financing round, etc.）。As the original inventor of the atrial shuntCorvia MedicalAlso moved on from the setbacks of 2022 and embarked onCorvia's New Clinical Study (RESPONDER-HF). And it has also regained capital favor, from 2022 to present.Corvia MedicalA total of $109 million in financing has been completed (including $54 million in mid-2022 and $55 million today). We look forward to the atrial shunt device experiencing a phoenix-like rebirth, just like RDN.
CorviaIt is a heart failure treatment product via femoral vein and atrial septum.CorviaIt is a coin-sized implant that is implanted during minimally invasive surgery, designed to create a channel between the left and right atria. By allowing decompression of the left atrium,CorviaCan address elevated pressures that cause heart failure symptoms。CorviaComposed of two parts: the implant and the delivery system;'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
The implant is a self-expanding metal cage-like device with a dual-disc design and a central opening. The implant is radiopaque and provides ultrasound feedback, allowing it to be visualized during the implantation process. Each side of the implant has nine legs, with the LA side featuring radiopaque markers at the end of each leg. The LA side of the implant is flat to allow the legs to lie flush with the LA wall, minimizing the LA profile when the implant is deployed. The right atrial side is curved to accommodate variable septal wall thickness, with only the leg tips contacting the right atrial wall. When fully expanded, the outer diameter of the implant is 19.4mm and the inner diameter is 8mm.
Corvia MedicalA company dedicated to revolutionizing the treatment of heart failure by developing groundbreaking structural heart devices. CorviaIs the world's first company approved by the EU for the use of transcatheter devices in the treatment of heart failure, used for HFpEF or HFmrEF.
